Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
Amir Avan(University of Pisa), Elisa Giovannetti(University of Pisa), Gerrit‐Jan Schuurhuis(Amsterdam UMC Location Vrije Universiteit Amsterdam), Olaf van Tellingen(Dutch Cancer Society), Godefridus J. Peters(Gdańsk Medical University), Tonny Lagerweij(Amsterdam University Medical Centers), Daniela Campani(University of Pisa), Niccola Funel(IMT School for Advanced Studies Lucca), D. Fuchs(FujiFilm VisualSonics (Canada)), Elena Galvani(University of Parma), Ugo Boggi(University of Pisa), Viola Caretti(University of Pisa), Mina Maftouh(Mashhad University of Medical Sciences), Henk M.W. Verheul(Erasmus MC Cancer Institute), Thomas Würdinger(Amsterdam University Medical Centers), Richard J. Honeywell(Amsterdam University Medical Centers)
Cited by 89
Related Papers
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
|New England Journal of Medicine|2012|5.5k
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
|The Lancet Oncology|2015|2.6k
The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions
|The Journal of Experimental Medicine|2007|2.3k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k